Zacks Investment Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Zacks Investment Management’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-21,597	Closed	-$50K	–	644
2018 Q2	$50K	Hold	21,597	–	–	﹤0.01%	536
2018 Q1	$69K	Hold	21,597	–	–	﹤0.01%	510
2017 Q4	$89K	Sell	21,597 -2,400	-10%	-$10.4K	﹤0.01%	556
2017 Q3	$108K	Hold	23,997	–	–	﹤0.01%	566
2017 Q2	$80K	Sell	23,997 -68	-0.3%	-$282	﹤0.01%	574
2017 Q1	$222K	Buy	+24,065	New	+$211K	0.01%	556
2016 Q3	–	Sell	-11,232	Closed	-$138K	–	794
2016 Q2	$138K	Buy	+11,232	New	+$136K	﹤0.01%	598

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Zacks Investment Management's OMED Position: Q3 2018 in Review

Zacks Investment Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2018, closing a stake of 21,597 shares — an estimated $50K sold.

Zacks Investment Management first reported a position in OMED in Q2 2016 and held it in 7 quarters. The position peaked at $222K in Q1 2017. 54 funds tracked by Wall St. Rank hold OMED as of Q3 2018.

Zacks Investment Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Zacks Investment Management sold 21,597 OncoMed Pharmaceuticals, Inc. shares in Q3 2018, an estimated $50K.
Zacks Investment Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2016 and held it in 7 quarters.
Zacks Investment Management's OncoMed Pharmaceuticals, Inc. position peaked at $222K in Q1 2017.
54 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2018.

Based on Zacks Investment Management's 13F filing for Q3 2018, filed 14 Nov 2018.